Assembly Biosciences Posts $0.93 Per-Share Loss and $2.96 Million in Third-Quarter Revenue
Key Facts
Assembly Biosciences posted an adjusted loss of $0.93 per share in the third quarter of 2026, compared with Zacks’ average forecast for a loss of $0.44, according to Zacks Research data published via Yahoo Finance. Zacks estimated the negative earnings surprise at 111.36%. The results cover the quarter ended in September 2026, with the actual loss exceeding the published estimate for the quarter. The company also reported revenue of $2.96 million for the period. The loss and revenue were the main items in the quarterly results data.
Assembly Biosciences’ revenue was $2.96 million in the third quarter, compared with $10.79 million in the corresponding period of 2025, according to Zacks data published via Yahoo Finance. This shows a decline in revenue between the two periods, while the company posted an adjusted loss of $0.93 per share. The year-over-year comparison provides context for the quarter’s revenue, while the $10.79 million figure applies specifically to last year’s third quarter. The current-quarter result was reported alongside Zacks’ average forecast for a loss of $0.44 per share. Zacks estimated the gap between the result and forecast as a negative earnings surprise of 111.36%.
On September 8, 2026, Assembly Bio announced that it had selected a 40% share of development costs and U.S. profits for its helicase-primase inhibitor program for recurrent genital herpes, as part of its collaboration with Gilead. The agreement links the company to spending on the program’s development and to its potential U.S. profits in line with the announced share. The company said GS-1179 is expected to advance to a Phase 2 clinical trial in participants with recurrent genital herpes before the end of 2026. That timing places the program’s next clinical development during the remaining weeks of the year. The information provided did not include a result from the trial or a more specific timing than before the end of 2026.
In the company’s latest reported liquidity figures, cash, cash equivalents and marketable securities totaled $320.4 million on June 30, 2026, compared with $226.6 million on March 31. The company had said its cash position, including the first $75 million extension fee due from Gilead in the fourth quarter of 2026, was expected to fund operations through 2029. That projection dates to a company disclosure in August 2026 and is therefore tied to the liquidity figures and estimates in that disclosure. The fee is due in the fourth quarter of the year, while the expected funding horizon extends through 2029. The information provided included no more recent update to that projection following the third-quarter results announcement.
Assembly Biosciences shares closed at $20.18 on November 12, 2026, down 9.79% in the session, according to Investing.com. The decline coincided with the release of third-quarter results, which included an adjusted loss of $0.93 per share and revenue of $2.96 million. Zacks data also showed that the loss exceeded its average forecast of $0.44 per share. The available information did not include an explanation from the company or the market for the share move in that session.